Form 4: Esperion Therapeutics Director Acquires Shares and Options
SEC Form 4 Filing
Director J. Martin Carroll acquired 23,000 shares of Esperion Therapeutics common stock and options to purchase 32,500 shares on May 23, 2024.
Summary
- On May 23, 2024, J. Martin Carroll, a director of Esperion Therapeutics, acquired 23,000 shares of common stock at $0 per share.
- Carroll also acquired options to purchase 32,500 shares of common stock at an exercise price of $2.25, expiring on May 23, 2034.
- These options vest fully on the earlier of May 23, 2025, or the Issuer's next annual meeting of stockholders following May 23, 2024.
- Following these transactions, Carroll directly owns 64,650 shares of Esperion Therapeutics common stock and options to purchase 32,500 shares.
- A Limited Power of Attorney was granted on June 1, 2022, authorizing Sheldon Koenig and Benjamin Looker to act on Carroll's behalf for SEC filings.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- A director's acquisition of shares and options may signal confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment regarding the company's prospects.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical sector.
- Comparing the size and frequency of insider transactions at Esperion Therapeutics to those of its peers, such as Amgen or Regeneron, could provide a benchmark for assessing the significance of this activity.
- For example, if other directors at Esperion or similar companies are also acquiring shares, it could signal a broader positive sentiment within the industry.
Stakeholder Impact
- The director's purchase may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2022-06-01 | Limited Power of Attorney executed, granting authority to Sheldon Koenig and Benjamin Looker for SEC filings. |
| 2024-05-23 | Date of transaction: Director acquired shares and options. |
| 2024-05-23 | Options vest on the earlier of this date in 2025 or the next annual stockholder meeting after this date in 2024. |
| 2034-05-23 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.